Immune Thrombocytopenia (ITP) Clinical Trials and Treatments

In ITP, the immune system makes antibodies against platelets, the cell fragments that plug damaged blood vessels and stop bleeding. Marked platelets are destroyed in the spleen faster than the bone marrow can replace them, and the same immune attack also quietly suppresses the marrow's platelet factories (megakaryocytes). The result is a platelet count that can fall from a normal 150,000 or more per microliter to below 30,000, and in severe cases below 10,000, where the risk of serious bleeding rises sharply.

The most common symptoms of Immune Thrombocytopenia include Easy or excessive bruising, often without a remembered injury, Pinpoint red or purple dots on the skin (petechiae), usually on the lower legs, Bleeding from the gums or frequent nosebleeds, Cuts that bleed longer than normal, Unusually heavy menstrual periods, among others. Estimated 9 to 20 per 100,000 people; children often have a temporary form that resolves within months. Symptoms can range from mild to severe and may vary between individuals.

Trial Friend lists all active clinical trials for Immune Thrombocytopenia from ClinicalTrials.gov, with eligibility criteria translated into plain English. Patients can filter by trial phase and recruitment status, search by location, and use the Match Me tool to score trials against their profile. ITP has one of the deeper medicine cabinets in rare hematology, which changes how to think about trials: they are often about finding a better-tolerated or longer-lasting option rather than a first option. Corticosteroids and IVIG remain first-line rescue treatments.

Yes. As of October 21, 2026, 8 FDA-approved medicines have a current label that names Immune Thrombocytopenia: Alvaiz (eltrombopag choline), first approved in 2023; Doptelet (avatrombopag), first approved in 2018; Nplate (romiplostim), first approved in 2008; Promacta (eltrombopag), first approved in 2008; Tavalisse (fostamatinib), first approved in 2018; Wayrilz (rilzabrutinib), first approved in 2025; Corticosteroids (prednisone, prednisolone, methylprednisolone, dexamethasone, hydrocortisone); and Immune globulin (immune globulin (human)). Corticosteroids and immune globulins count once each.

The exact cause of Immune Thrombocytopenia is not fully understood. It is not caused by a single gene; inherited variants raise risk, and immune, environmental or other triggers are thought to set it off. Autoimmune diagnosis of exclusion; there is no genetic or antibody test that confirms ITP. Estimated 9 to 20 per 100,000 people; children often have a temporary form that resolves within months. Research is ongoing to better understand the disease mechanism.

No single gene test diagnoses Immune Thrombocytopenia. The diagnosis rests on clinical findings and laboratory or imaging results; genetic variants shift risk rather than cause the disease. Autoimmune diagnosis of exclusion; there is no genetic or antibody test that confirms ITP.

Some trials collect genetic samples for research or check specific risk markers. The Genetic Testing section of this page shows any tests listed in the NIH Genetic Testing Registry, which for this condition are usually research or risk-marker tests rather than diagnostic ones.

Eligibility for Immune Thrombocytopenia clinical trials depends on factors like age, diagnosis, treatment history, and overall health. Each trial sets its own inclusion and exclusion criteria. Trial Friend translates these requirements from medical language into plain English so patients can review them more easily. The Match Me tool can score your profile against active trials to help identify studies that may be a fit.

Participating in a Immune Thrombocytopenia clinical trial typically involves scheduled visits, medical tests, and close monitoring by a research team. Depending on the study phase, you may receive an investigational treatment, a placebo, or the current standard of care. Trials may last from a few weeks to several years. Study participation is voluntary, and you can withdraw at any time.